Filing Flows

Filing Flows › Companies › Editas Medicine › Cash flow

Editas Medicine cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$29.7M in Q2 2026 · −$121M over twelve months

Operating cash flow−$29.6M
Capital spending−$106K
Free cash flow−$29.7M

Analysis

In Q2 2026, Editas Medicine generated −$29.6M of operating cash flow and spent $106K on capital projects, leaving free cash flow of −$29.7M. That is $20.5M more than in Q2 2025 (−$50.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$120M; the largest uses were operating cash flow ($120M), capital spending ($691K); besides operations, cash came from shares issued ($152M), other investing ($10.6M); the cash balance rose by $42.1M.

Operating cash flow was −$29.6M against net income of −$18.2M. The largest differences: deferred revenue −$8.2M, accrued liabilities −$4.0M, stock-based pay +$2.2M.

Free cash flow

Editas Medicine: free cash flow by quarterEditas Medicine: free cash flow by quarter−$55.5MQ3 2024−$51.3MQ4 2024−$47.9MQ1 2025−$50.2MQ2 2025−$31.3MQ3 2025−$36.4MQ4 2025−$23.2MQ1 2026−$29.7MQ2 2026
Operating cash flow less capital spending.
Editas Medicine: operating cash flow against capital spendingEditas Medicine: operating cash flow against capital spendingOperating cash flowCapital spending−$52.6M$2.9MQ3 2024−$50.8M$540KQ4 2024−$47.8M$114KQ1 2025−$50.2M$0Q2 2025−$30.8M$433KQ3 2025−$36.4M$60KQ4 2025−$23.1M$92KQ1 2026−$29.6M$106KQ2 2026
Latest (Q2 2026): Operating cash flow −$29.6M, Capital spending $106K.

Capital allocation, year by year

Editas Medicine: where the cash came from (up) and went (down), by fiscal yearEditas Medicine: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$164MFY2021: Shares issued $281MFY2021: Capital spending −$8.0M$281MFY2021FY2022: Operating cash flow −$177MFY2022: Shares issued $305KFY2022: Capital spending −$4.1M$305KFY2022FY2023: Operating cash flow −$132MFY2023: Shares issued $117MFY2023: Capital spending −$4.7M$117MFY2023FY2024: Operating cash flow −$210MFY2024: Net borrowing $57.0MFY2024: Shares issued $193KFY2024: Capital spending −$8.8M$57.2MFY2024FY2025: Operating cash flow −$165MFY2025: Net borrowing −$2.9MFY2025: Shares issued $42.9MFY2025: Capital spending −$607K$42.9MFY2025
Over these 5 years operating cash flow totalled −$849M; the largest uses were operating cash flow ($849M) and capital spending ($26.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$212M
Debt$55.7M
Net cash$156M
Due within a year$7.5M
Cash runway21 months

Editas Medicine is burning cash: its operations consume cash, a free cash flow of −$121M a year at the current rate against $212M of cash and investments: a runway of about 21 months; $7.5M of debt also comes due within a year, which the cash covers before any new financing.

Where the cash came from and went

Editas Medicine: sources (+) and uses (−) of cash, Q2 2026Editas Medicine: sources (+) and uses (−) of cash, Q2 2026Shares issued$117MCash drawn (+) / kept (−)−$58.2MOther investing−$29.7MOperating cash flow−$29.6MCapital spending−$106KOther financing$36K
Editas Medicine: sources (+) and uses (−) of cash, TTM to Q2 2026Editas Medicine: sources (+) and uses (−) of cash, TTM to Q2 2026Shares issued$152MOperating cash flow−$120MCash drawn (+) / kept (−)−$42.1MOther investing$10.6MCapital spending−$691KOther financing$196K

From profit to cash

Editas Medicine: net income to operating cash flow, Q2 2026Editas Medicine: net income to operating cash flow, Q2 2026Net income−$18.2MDepreciation & amortization$416KStock-based pay$2.2MOther non-cash−$128KReceivables−$133KPayables−$58KAccrued liabilities−$4.0MDeferred revenue−$8.2MPrepaid and other assets−$1.9MOther liabilities−$454KOperating cash flow−$29.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$29.6M−$106K—$117M−$58.2M−$29.7M
Q1 2026−$23.1M−$92K——$23.0M−$23.2M
Q4 2025−$36.4M−$60K—$17.1M$19.0M−$36.4M
Q3 2025−$30.8M−$433K—$17.2M−$25.9M−$31.3M
Q2 2025−$50.2M——$7.2M$150K−$50.2M
Q1 2025−$47.8M−$114K−$2.9M$1.4M−$7.2M−$47.9M
Q4 2024−$50.8M−$540K—$1K−$35.7M−$51.3M
Q3 2024−$52.6M−$2.9M——−$31.4M−$55.5M

Editas Medicine: income statement and cash flow

Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%. The chart follows the revenue to costs, profit and cash.

Editas Medicine: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.